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Abstract: It has been proposed that blood coagulation factors, principally factor X (FX), enhance
the uptake of human adenovirus type 5 (Ad5) into cultured epithelial cells by bridging the viral
hexon capsid protein and cell-surface heparan sulphate proteoglycans (HSPGs). We studied the
effects of FX on Ad transduction of lymphoid cell lines (NK92MI, a natural killer cell line; Daudi,
a B-cell line and Jurkat, a T-cell line) as well as primary peripheral blood lymphocytes (PBL) and
HeLa epithelial cells using either replication-deficient Ad5, or a derivative in which the Ad5 fiber
was replaced with that of another Ad type, Ad35, termed Ad5F35. PBL and NK92MI were resistant
to Ad5 transduction. Transduction of Jurkat and Daudi cells by Ad5 was reduced by FX but without
discernible effects on cell-surface Ad5 binding. FX reduced virus binding and transduction of
all lymphoid cell lines by Ad5F35, as well as transduction of the T- and Natural Killer (NK)-cell
populations of PBL. Flow cytometry analysis showed that all lymphoid cell lines were negative for
HSPG components, in contrast to HeLa cells. FX reduced transduction of an HSPG-negative mutant
Chinese hamster ovary cell line (CHOpgsA745) by Ad5 and Ad5F35, with Ad5F35 binding also being
reduced by FX. These results point to fiber-dependent differences (Ad5 versus Ad35 fiber) in Ad
binding to and transduction of human lymphoid and epithelial cells in the presence of FX.
Keywords: adenovirus; factor X; lymphoid cells; blood lymphocytes; virus entry
1. Introduction
Extensive studies in cultured cells in vitro have shown that human adenoviruses (Ads) enter
human cells by a two-step process: a primary interaction between the Ad fiber and cell-surface
attachment molecules followed by an interaction between the penton base and cell-surface integrins
αvβ3 and αvβ5. The three major cell-surface attachment molecules used by Ads in vitro are
the Coxsackie and adenovirus receptor, CAR, (utilized by most Ads including type 5, Ad5),
CD46 (a complement inhibitor protein utilized by certain types such as Ad35) and Desmoglein 2
(utilized by types such as Ad3) [1–3]. In contrast, intravenous delivery of Ad5 in rodents and nonhuman
primates resulted in attachment molecule-independent accumulation of virus in the liver [4–6]. Further
studies showed that blood coagulation factor X (FX) mediated liver tropism in vivo [7,8]. FX binds
to hypervariable regions of the major capsid protein, the hexon, and has been proposed to act as a
bridge between heparan sulphate proteoglycans (HSPGs) on target cells and hexon trimers in the
virus capsid [9–13]. However, mice in which Ext1 (an enzyme required for HS biosynthesis) was
deleted showed no significant reduction in liver transduction in vivo by Ad5, thus questioning a role
for HSPGs in Ad entry into cells in vivo [14]. A hybrid Ad, in which the Ad5 fiber was replaced with
that of Ad35 (Ad5F35), exhibited reduced liver and increased lung tropism in the presence of FX [15].
Investigations of Ad interactions with cells and proteins of the blood are important for their
application as safe and efficient viral gene therapy vectors that can be delivered intravenously.
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Such studies should lead to the design of modified viruses that combine the required tissue tropism
and optimal levels of transduction. Hybrid viruses can also be useful tools in dissecting differences in
the activities of specific proteins of different Ad types in the context of whole virus genomes.
Previous studies have shown that human blood lymphocytes and certain lymphoid cell lines
are relatively refractory to transduction by Ad5 but are readily transduced by Ad5F35, although the
influence of FX in this cell system has not been examined [16–21].
In this study, we have investigated the interactions between Ads (Ad5 and Ad5F35), blood
coagulation factors (principally FX) and lymphoid cells. In contrast to previous studies on human
epithelial cells, we find that FX treatment of lymphoid cell lines and PBL reduces transduction by
Ad5F35, an effect that is accompanied by reduced virus binding to cells. The lymphoid cell lines found
here to express very low levels of cell-surface HSPG and an HSPG-negative Chinese hamster ovary
(CHO) cell line (in which HSPG biosynthesis was genetically ablated) also showed reduced levels of
transduction and virus binding by Ad5F35 when treated with FX. The lack of enhancement of Ad
binding to lymphoid cells in the presence of FX can be explained by their greatly reduced level of
HSPG. However the mechanism of FX-mediated inhibition of Ad5F35 binding and cell transduction
requires further investigation. Thus there are fiber-dependent and cell-specific effects of FX on Ad
entry. Our results suggest that plasma FX may exert a protective effect on lymphoid cells against
Ad entry.
2. Materials and Methods
2.1. Materials
FX and FXII were purchased from Haematologic Technologies (Essex Junction, VT, USA).
The Fluorescein isothiocyanate (FITC)-labelled antihuman HSPG antibody termed 10E4 (clone 8.S.087)
was purchased from US Biologicals (Salem, MA, USA), the antihuman CAR antibody (clone E1-1)
was purchased from Abcam (Cambridge, UK) and the FITC-labelled antihuman CD46 (clone E4.1),
PE-labelled antihuman CD19 (clone HIB19), APC-labelled antihuman CD56 (clone B159) and APC-Cy7
labelled antihuman CD3 (clone SK7) antibodies were purchased from BD Bioscience (Oxford, UK).
2.2. Cell Lines
HeLa cells (obtained from the European Collection of Authenticated Cell Cultures (ECACC),
Salisbury, UK) and CHO cells were cultured in Dulbecco’s Minimal Eagle Medium (DMEM;
Sigma-Aldrich, Dorset, UK) supplemented with 10% Foetal Bovine Serum (GE Healthcare,
Buckinghamshire, UK), 2 mM L-glutamine, 50 units penicillin/mL and 50 µg streptomycin/mL
(Sigma-Aldrich); this supplemented DMEM is hereafter referred to as “complete DMEM”.
CHOpgsA745 cells (a kind gift from Prof. David J Evans, University of Glasgow, Glasgow, UK)
were cultured in Ham’s F12 medium (Sigma-Aldrich) supplemented with 10% Foetal Bovine
Serum (GE Healthcare, Little Chalfont, UK), 2 mM L-glutamine, 50 units penicillin/mL and 50 ng
streptomycin/mL (Sigma-Aldrich). NK92MI, Daudi and Jurkat cells were cultured in Roswell
Park Memorial Institute 1640 Media (RPMI; Sigma-Aldrich) supplemented with 10% Foetal Bovine
Serum (GE Healthcare), 2 mM L-glutamine, 50 units penicillin/mL and 50 ng streptomycin/mL
(Sigma-Aldrich); supplemented RPMI 1640 is hereafter referred to as “complete RPMI”. Adherent cells
were detached using trypsin/EDTA (Sigma-Aldrich). All cells were grown at 37 ◦C in a humidified
atmosphere of 5% CO2.
2.3. Viruses
Ad5-EGFP (Enhanced Green Fluorescent Protein) is a replication-deficient E1- and E3-deleted
adenovirus based on Ad5 in which the E1 region was replaced with a cytomegalovirus (CMV)
promoter-driven EGFP transgene and was a kind gift from Prof. Aviva M Tolkovsky, University of
Cambridge, UK [22]. Ad5F35-EGFP is identical to Ad5-EGFP virus except that the Ad35 fiber replaced
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the Ad5 fiber and was kindly provided by Prof. Masatoshi Tagawa (Chiba, Japan) [23]. The viruses
were propagated in 911 cells and purified using the freeze-thaw method followed by caesium chloride
centrifugation [24]. The number of virus particles (vp) was determined by spectrophotometry,
as previously described [25].
2.4. Flow Cytometric Detection of Cell-Surface Molecules
Adherent cell lines were detached using Versene (Sigma-Aldrich) followed by addition of complete
DMEM, centrifugation at 350× g for 5 min and resuspension in Phosphate-buffered saline (PBS) + 1%
Bovine Serum Albumin (BSA). Cell lines growing in suspension were centrifuged at 350× g for
5 min and resuspended in PBS + 1% BSA. Each sample for flow cytometry comprised 2.5 × 105 cells.
Cells were incubated with 1% (final concentration) mouse serum (for CD46) or goat serum (for CAR)
for 10 min on ice (to block non-specific immunoglobulin binding sites) followed by addition of PBS.
Cells were collected by centrifugation (350× g, 5 min) and incubated with FITC-mouse-anti-CD46 or
mouse anti-CAR for 30 min on ice, washed twice in PBS with centrifugation (350× g, 5 min). Binding
of primary CAR antibody was detected by incubation for 30 min on ice with a FITC-labelled goat
anti-mouse Ig antibody. Cells were washed twice in PBS with centrifugation (350× g, 5 min), analyzed
by flow cytometry on a FACSCalibur, (BD Bioscience, Wokingham, UK) and the data analyzed using
FlowJo software (Tree Star, Ashland, OR, USA).
2.5. Transduction of Lymphoid Cell Lines
Cells (2.5× 105) were centrifuged at 350× g for 5 min and washed once with PBS. The supernatant
was removed, cells were resuspended in serum-free RPMI and exposed to Ad5-EGFP or Ad5F35-EGFP
along with FX or FXII (1 unit/mL final concentration). Cells were incubated for one hour at 37 ◦C in a
humidified atmosphere with 5% CO2, 1 mL of complete RPMI 1640 medium was added and incubated
at 37 ◦C for a further 24 h in a humidified atmosphere with 5% CO2. The cells were collected by
centrifugation, washed in PBS with centrifugation (350× g, 5 min) and resuspended in PBS. Cells were
analyzed by flow cytometry as described above.
2.6. Transduction of Adherent Cell Lines
Cells (5 × 104) were plated in 6 well plates and incubated for 24 h at 37 ◦C in a humidified
atmosphere with 5% CO2. The cells were washed with PBS followed by addition of Ad5-EGFP or
Ad5F35-EGFP in serum-free DMEM (for CHO and HeLa cells) or Ham’s F12 (for CHOpgsA745 cells)
with appropriate supplements: FX or FXII (1 unit/mL). The cells were incubated for one hour at
37 ◦C in a humidified atmosphere with 5% CO2, complete DMEM or Ham’s F12 added and incubated
for a further 24 h in a humidified atmosphere with 5% CO2. The cells were detached by addition
of trypsin-EDTA followed by neutralization with “complete” medium, collected by centrifugation,
washed by addition of PBS with centrifugation and resuspension in PBS. Cells were analyzed by flow
cytometry as described above.
2.7. Fluorescent Labelling of Adenoviruses
Virus particles (1.1× 1012) were dialysed in Molecular Weight Cut-Off (MWCO) 7000 dialysis cassettes
(ThermoFisher Scientific, Warrington, UK) against 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulphonic
acid (HEPES)-KOH (pH 8.0) to remove glycerol. Alexa Fluor 488 carboxylic acid succinimidyl ester
(50 µg, Invitrogen, Carlsbad, CA, USA) was added and incubated for 1 h on a vibrating platform.
The reaction was quenched using 1.5 M hydroxylamine hydrochloride and incubated for 30 min on a
vibrating platform. Excess fluorophore was removed by overnight dialysis as described above.
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2.8. Virus: Cell Binding
Adherent cells were detached by incubation with Versene at 37 ◦C, addition of complete medium
and centrifugation (350× g, 5 min). The cells were washed by addition of PBS and centrifugation at
350× g for 5 min, resuspended in binding buffer (PBS + 0.5% BSA + 1 mM MgCl2 + 1 mM CaCl2)
and incubated with Alexa Fluor 488-labelled viruses for 1 h on ice. The cells were washed twice by
addition of binding buffer with centrifugation at 350× g for 5 min and analyzed by flow cytometry as
described above.
2.9. Isolation of Peripheral Blood Mononuclear Cells (PBMC)
Blood samples were collected following the receipt of informed consent and ethical review by
the Leeds Teaching Hospitals National Health Service Trust (REC number 10-H1306-7, awarded
7 January 2010). Peripheral venous blood (12 mL) was removed from healthy donors and collected
in Vacutainer Blood Collection tubes (BD Bioscience). The blood was diluted with an equal volume
of sterile PBS, layered onto 15 mL Lymphoprep (Axis-Shield, Dundee, UK) at room temperature in a
50 mL centrifuge tube and centrifuged at 850× g for 20 min at 20 ◦C without braking. The resulting
cloudy layer in the tube was transferred to a 50 mL centrifuge tube, 40 mL PBS was added and
centrifuged at 200× g for 10 min at 20 ◦C. The supernatant was carefully removed by inverting the
tube and the cells resuspended in 10 mL PBS.
2.10. Transduction of PBMC
PBMCs (2.5 × 105) were centrifuged at 350× g for 5 min at 4 ◦C, the supernatant removed and the
cells resuspended in either Ad5-EGFP or Ad5F35-EGFP in serum-free RPMI with or without 1 unit
FX/mL and incubated for one hour at 37 ◦C in a humidified atmosphere with 5% CO2. Complete RPMI
1640 was added to each sample and incubated for a further 24 h at 37 ◦C in a humidified atmosphere
with 5% CO2. The cells were centrifuged at 350× g for 5 min at 4 ◦C, resuspended in 1 mL PBS and
centrifuged at 350× g for 5 min at 4 ◦C. The supernatant was removed and Allophycocyanin (APC)-Cy7
anti-CD3, APC anti-CD56 and Phycoerythrin (PE) anti-CD19 were added. Cells were incubated on
ice for 30 min and washed twice by addition of 1 mL PBS with centrifugation at 350× g for 5 min at
4 ◦C. The cells were resuspended in 500 µL PBS, 3 µL propidium iodide (PI) solution (Sigma-Aldrich,
1 mg/mL) was added and incubated for 20 min at room temperature. The samples were analyzed by
flow cytometry using a FACSAria (BD Bioscience, Wokingham, UK) and the data analyzed using DiVa
software (BD Bioscience, Wokingham, UK).
3. Results
3.1. Adenovirus Transduction of Lymphoid Cell Lines
Expression of primary cell-surface attachment molecules required for adenovirus entry was
examined in lymphoid cell lines that represent the major immune cells of blood: NK92MI (an NK
cell line), Jurkat (a T-cell line) and Daudi (a B-cell line). HeLa epithelial cells (which support Ad
replication) were used as a positive control (Figure 1A). Cell-surface CD46 was detected on all
cell lines, whereas low levels of CAR and Dsg-2 were present on Jurkat and Daudi cells. NK92MI cells
were negative for CAR and Dsg2. This suggested that Ads that interact with CD46 (such as Ad35)
may be able to enter lymphoid cells. Therefore the lymphoid cell lines were incubated with two
replication-deficient viruses, Ad5-EGFP and Ad5F35-EGFP [22,23], at a temperature that permitted
transduction (37 ◦C). Transduction is herein defined as a process that includes virus binding,
internalization, trafficking through the cytoplasm to the nuclear pore, transport of the Ad genome to the
nucleus and transcription and detection of the product of a virus-encoded expression cassette (EGFP).
In both viruses, the essential viral E1A and E1B genes were replaced with the EGFP gene. Ad5F35-EGFP
is identical to Ad5-EGFP except that the Ad5 fiber was replaced with that of Ad35. Cells were
exposed to each virus at three different vp (virus particle): cell ratios (Figure 1B). Transduction of
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HeLa cells at the lowest vp:cell ratio (103 vp:cell) with either virus resulted in approximately 100%
EGFP-positive cells. Transduction in all cell lines by the CD46-interacting Ad5F35-EGFP occurred
in a manner dependent on the vp:cell ratio (Figure 1B). However, only cell lines that expressed
CAR showed transduction by Ad5-EGFP, namely Jurkat and (at a much lower level) Daudi cells.
CAR-negative NK92MI cells did not exhibit transduction by Ad5-EGFP at any vp:cell ratio. These
results indicated that, in the absence of extracellular factors, transduction by Ads was dependent on
the presence of cell-surface attachment molecules.
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2) and cluster of differentiation 46 (CD46) was measured on a panel of lymphoid cell lines (NK92MI, 
Jurkat and Daudi) using flow cytometry. HeLa cells, which support Ad replication, served as a 
positive control; (B) The lymphoid cells were transduced with either Adenovirus 5-Enhanced Green 
Fluorescent Protein (Ad5-EGFP) or Ad5F35-EGFP at the indicated vp:cell ratios. EGFP expression was 
measured after 24 h by flow cytometry, the percentage of EGFP-positive cells was determined and 
expressed as % transduction. In (A,B), three experimental replicates were performed (n = 3) with all 
samples assayed in triplicate. 
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Jurkat and Daudi lymphoid cell lines. The presence of FX did not change the refractory nature of 
NK92MI cells to Ad5-EGFP transduction. FX significantly reduced Ad5F35-EGFP transduction of the 
lymphoid cell lines as well as HeLa cells. This indicated that FX had not only fiber-specific effects but 
also cell type-specific effects on Ad transduction of human cells. 
To determine if these effects were also shown by any other coagulation factor, the effects of Factor 
XII (FXII) on Ad transduction were analyzed (Figure 2B). The lymphoid cell lines and HeLa cells were 
exposed to each Ad in the presence of a physiological concentration of FXII. Interestingly, the presence 
of FXII resulted in a minor enhancement of Ad5-EGFP transduction of Jurkat, but not Daudi or HeLa 
cells. Furthermore, FXII significantly reduced Ad5F35-EGFP transduction of NK92MI cells but not 
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FXII. EGFP expression was measured after 24 h by flow cytometry. (C) Lymphoid cells were 
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Figure 2. Effect of coagulation factors on adenovirus binding to and transduction of lymphoid and HeLa
cells. Lymphoid and HeLa cells were transduced with either Ad5-EGFP or Ad5F35-EGFP (refs [20,21]),
at a 104 vp:cell or a 103 vp:cell ratio respectively, in the presence or absence of (A) FX or (B) FXII.
EGFP expression was measured after 24 h by flow cytometry. (C) Lymphoid cells were incubated with
104 vp:cell Alexa Fluor 488-labelled Ad5-EGFP or Ad5F35-EGFP on ice for one hour. The cells were
washed with PBS and the bound fluorescence measured by flow cytometry. The values given are the
geometric mean of either EGFP expression (A,B) or Alexa Fluor 488 fluorescence (C) relative to the
geometric mean in the absence of FX. * = p < 0.05, ** = p < 0.01 and *** = p < 0.001 based on a one sample
test. T r e xperimental replicat s were p rformed (n = 3) with all samples ssayed in triplicate.
n/s: not significant.
To determine if these effects were also shown by any other coagulation factor, the effects of Factor
XII (FXII) on Ad transduction were analyzed (Figure 2B). The lymphoid cell lines and HeLa cells were
exposed to each Ad in the presence of a physiological concentration of FXII. Interestingly, the presence
of FXII resulted in a minor enhancement of Ad5-EGFP transduction of Jurkat, but not Daudi or HeLa
cells. Furthermore, FXII significantly reduced Ad5F35-EGFP transduction of NK92MI cells but not
Jurkat, Daudi or HeLa cells. Thus a consistent and significant reduction in Ad transduction of the
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lymphoid cell lines by FXII was not found, in contrast to the generally downregulatory effects of FX on
Ad5- and Ad5F35-EGFP-mediated transduction of lymphoid cell lines.
To test if the FX-mediated reduction in transduction involved reduced virus binding at the cell
surface, lymphoid and HeLa cells were incubated on ice with Alexa Fluor 488-labelled Ad5-EGFP or
Ad5F35-EGFP and bound virus measured by flow cytometry (Figure 2C). FX significantly enhanced
Ad5-EGFP binding to HeLa cells but had no effect on binding to the lymphoid cell lines. Ad5F35-EGFP
binding to HeLa cells was significantly enhanced in the presence of FX while binding to the lymphoid
cell lines was significantly reduced. Therefore, FX also has fiber- and cell type-specific effects on
binding of Ads to attachment molecules on the cell surface. Notably, in HeLa cells, FX enhanced
both transduction and binding of Ad5-EGFP whereas transduction by Ad5F35-EGFP was reduced
by FX, although binding to cells was enhanced. The latter observation might suggest that FX may
also modulate intracellular events that are involved in delivering Ad5F35-EGFP to the nucleus of
epithelial cells.
3.3. Effect of Factor X on Adenovirus Transduction of Primary Blood Lymphoid Cells
To determine whether the FX-mediated reduction in Ad5-EGFP and Ad5F35-EGFP transduction
detected in lymphoid cell lines had physiological relevance, peripheral blood lymphocytes (PBL) were
studied. The T-, B- and NK-cell lymphocyte populations were identified and expression of CAR and
CD46 was measured by flow cytometry. CAR was not detected in any of these lymphocyte populations.
In contrast, CD46 was detected on all lymphocyte populations at levels that varied between donors
(Figure 3A). This suggested that incubation of these cells with Ad5F35-EGFP, but not Ad5-EGFP, might
result in transduction in the absence of FX. PBL isolated from two different donors (donors 4 and 5)
were incubated with either Ad5-EGFP or Ad5F35-EGFP (at a 105 vp:cell ratio), the lymphocyte
populations identified and EGFP expression measured. Ad5-EGFP showed no detectable transduction
of the lymphocyte populations. Transduction of all lymphocyte populations by Ad5F35-EGFP was
detected, particularly in T cells, as previously noted [16], although there was variability between
donors (Figure 3B). This indicated that the lymphocyte populations of PBL exhibited transduction by
Ad5F35-EGFP in an attachment molecule-dependent manner, consistent with the presence of CD46 on
their cell surface. The effect of FX on transduction of PBL by Ad5F35-EGFP was determined (Figure 3C).
In both donors 4 and 5, FX treatment resulted in a significant reduction in Ad5F35-EGFP-mediated
transduction of T cells and NK cells. While there was some reduction in transduction of B cells in both
donors, this did not reach statistical significance. Overall, the results obtained with PBL were similar
to those obtained with lymphoid cell lines in terms of a reduction in Ad5F35-EGFP transduction in
the presence of FX, giving physiological relevance to the reduction of Ad5F35-EGFP transduction
mediated by FX in lymphoid cell lines.
3.4. Role of HSPG Expression in FX-Mediated Adenovirus Transduction of Lymphoid Cells
As FX has been proposed to alter virus binding by connecting the virus to cell-surface
HSPGs, expression of HSPG was studied in the lymphoid cell lines. As controls, HSPG-positive
normal CHO cells and an HSPG-negative mutant CHOpgsA745 cell line (which is deficient in
xylosyltransferase, an enzyme that catalyses an initial step in the glycosaminoglycan component of
HSPG biosynthesis) [26], were used. Both CHO cell lines are negative for CAR and CD46. The presence
of cell-surface HSPG was analyzed by flow cytometry using the mouse monoclonal antibody termed
10E4 which detects a heparan sulphate epitope of HSPG [27]. As expected, wild-type CHO cells bound
the 10E4 antibody strongly and the HSPG-deficient mutant CHOpgsA745 cells were negative for 10E4
binding (Figure 4A). While HeLa epithelial cells were positive for 10E4 binding, the lymphoid cell
lines did not exhibit detectable 10E4 binding (Figure 4A). Previous studies have shown that the NK
and T cell populations of PBL were negative for cell-surface HSPG while B cells were positive [28].
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Figure 3. Reduction of Ad5F35-mediated tra s ction of primary T and Natural Killer (NK) cells by
Factor X. (A) Peripheral blood lymphocytes (PBL) were isolated from three healthy donors and the
expression of CD46 was analyzed on the lymphocyte populations; (B) PBL isolated from two healthy
donors were incubated with Ad5F35-EGFP at a 105 vp:cell ratio. EGFP expression in the lymphocyte
sub-population was measured after 24 h by flow cytometry; (C) PBL isolated from the same two
healthy donors as in (B) and incubated with Ad5F35-EGFP at a 105 vp:cell ratio in the presence or
absence of FX. EGFP expression in ach lymphocyte population was measured af er 24 h by flow
cytometry. The lymphocyte populations were identified by flow cytometric detection of cell-surface
CD3, CD19 and CD56 using appropriate monoclonal antibodies. B cells were classified as CD19+,
NK cells as CD19− CD56+ CD3− and T cells as CD19− CD56− CD3+. *** = p < 0.001 based on a two
tail student’s t test. Two experimental replicates were performed (n = 2) with all samples assayed in
triplicate. n/s: not significant.
CHO mutant cell lines offer the possibility of directly investigating the role of HSPG expression
in Ad binding and transduction. CHO and CHOpgsA745 cells were incubated on ice with Alexa Fluor
488-labelled Ad5-EGFP or Ad5F35-EGFP in the presence or absence of FX. Binding of Ad5-EGFP and
Ad5F35-EGFP virus particles to CHO cells was enhanced by FX by approx. 7- and 15-fold respectively.
However, FX had a negligible effect on Ad5-EGFP binding but significantly reduced Ad5F35-EGFP
binding to CHOpgsA745 cells (Figure 4B). Incubation of CHO and CHOpgsA745 cells with Ad5-EGFP
or Ad5F35-EGFP at 37 ◦C revealed that FX significantly enhanced Ad5-EGFP and Ad5F35-EGFP
transduction of CHO cells and dramatically reduced both Ad5-EGFP and Ad5F35-EGFP transduction
of CHOpgsA745 cells (Figure 4C).
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Figure 4. Heparan sulphate proteoglycan (HSPG) expression in lymphoid cells and the role of HSPGs
in FX-mediated adenovirus entry. (A) The expression of HSPGs on HeLa epithelial and the lymphoid
cell lines w s determined, along with CHO and HS-GAG-negative CHOpgsA745 cells (as positive and
negative controls respectively) by flow cytometry using a monoclonal antibody which recognises
the 10E4 epitope present on heparan sulphate glycosaminoglycans, a component of HSPG [27];
(B) To quantify virus binding, CHO and CHOpgsA745 cells were incubated with either Alex488-labelled
Ad5-EGFP or Ad5F35-EGFP at a ratio of 104 vp:cell in the presence or absence of FX on ice for one hour.
Unbound virus was removed by washing in PBS and the fluore ce ce meas by flow cytometry;
(C) CHO and CHOpgsA745 cells were incubated with either Ad5-EGFP or Ad5F35-EGFP at a 104 vp:cell
ratio in the presence or absence of FX. EGFP expression was measured after 24 h by flow cytometry.
The values given are the geometric mean of EGFP expression relative to the geometric mean in the
absence of FX. * = p < 0.05, ** = p < 0.01 and *** = p < 0.001 based on a one-sample t test. In (B,C),
three experimental replicates were performed (n = 3) with all samples assayed in triplicate.
4. Discussion
Viruses have evolved many mechanisms to attack, subvert and control host cells. Initial interactions
between viruses and host cells involve interactions at the cell surface followed by exploitation of host
cell structures and pathways following internalization of the virus. Although intracellular structures and
components have been a major focus of virology research, extracellular factors have relatively recently
been identified as modulating agents of virus entry and evasion of the host humoral immune system.
Factor X (FX) binds to the major adenovirus (Ad) capsid protein, the hexon, of most Ad types and has
been proposed to both enhance Ad entry into cells by interaction with cell-surface heparan sulphate
proteoglycans (HSPG) and protect the virus against inactivation by complement and IgM [12–15,29].
FX may therefore play a significant role in mediating Ad infection in vivo. Previous reports have mainly
focused on the effects of FX on Ad binding, uptake and expression in epithelial cells, such as human
HepG2, SKOV3 or A549 cells or nonhuman CHO cells [8–13,15,24]. In this study, interactions between Ads,
FX and human lymphoid cell lines or primary lymphocytes were examined since it seems likely that Ads
may encounter lymphoid cell types during natural infections [30] or when administered intravenously as
gene therapy vectors [4–7]. Two Ads were chosen for virus binding and cell transduction studies that
differed only in the origin of the viral fiber protein, namely Ad5-EGFP and Ad5F35-EGFP. In the latter
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virus, the Ad5 fiber was replaced with that of Ad35. This replacement alters the tropism of the virus from
CAR-interacting (Ad5) to CD46-interacting (Ad5F35). Both viruses contained the same Ad5 hexon protein
and an EGFP transgene for detection of virus-mediated transduction of target cells.
A panel of lymphoid cells was chosen to represent the main classes of blood lymphocytes: Jurkat
cells (a T-cell line), Daudi cells (a B-cell line) and NK92MI (an NK-cell line). Jurkat and Daudi cells
showed transduction by Ad5-EGFP and Ad35-EGFP, in agreement with previous studies [19]. NK92MI
cells were transduced by Ad5F35-EGFP but not by Ad5-EGFP, also as described [17], consistent with
the expression of CD46 but not CAR on the NK92MI cell surface (Figure 1).
FX significantly reduced the level of Ad5F35-EGFP transduction of all lymphoid cell lines as well
as the T- and B-cell populations of peripheral blood lymphocytes. Binding of fluorescently-labelled
Ad5F35-EGFP to the lymphoid cell lines was reduced by FX treatment, this varied between cell lines
with Daudi and NK92MI being most affected. FX also reduced Ad5-EGFP transduction of Daudi and
Jurkat cells but had no effect on fluorescently-labelled Ad5-EGFP binding to these cell lines, suggesting
that FX may interfere with intracellular processes involved, for example, in trafficking Ad5 virus
particles to the nucleus. In contrast, Ad5-EGFP binding to and transduction of HeLa epithelial cells
was stimulated by FX, as shown in many other studies with a variety of epithelial cell lines [8–13,24].
However, transduction of HeLa cells by Ad5F35-EGFP was greatly reduced by FX, even though binding
of this virus to HeLa cells was greatly enhanced by FX. These results point to cell-type differences
in Ad binding to and transduction of susceptible human cells—overall, there was a stimulation of
Ad transduction of epithelial cells but a reduction in transduction of lymphoid cells. Furthermore,
the presence of the Ad35 fiber appears to confer different virus binding and cell transduction properties
on Ad5F35-EGFP compared to Ad5-EGFP in response to FX, even in the same cell line.
The intracellular process that is modulated by FX during Ad5-EGFP and Ad5F35-EGFP
transduction of lymphoid and HeLa cells remains to be determined. Previous studies on the
effects of FX on Ad5F35 in CHO cells suggested that FX has increased stability in the lower pH
environment associated with the late endosome and that Ad5F35 particles could be detected in late
endosome/lysosomes [31]. Therefore it is possible that FX retains the Ad5F35-EGFP virus in late
endosomes, resulting in reduced escape into the cell and hence reduced transduction. Previous studies
on Ad5 infection of Daudi cells (in the absence of FX) have shown that Ad5 was detected in both late
and early endosomes [19]. Information on intracellular trafficking of Ad5F35 in lymphoid cells in the
presence of FX is not currently available, therefore this process needs to be studied to understand the
reduction of transduction found in this study.
Models for FX-mediated entry of Ad5 into epithelial cells include its role in the formation of
a bridge between hexon and the host cell. As HSPG has been shown to be dispensable in vivo for
this process [14], it is essential to investigate the mechanism of FX action involved in modulation of
attachment molecule-dependent entry. In this study, flow cytometric analysis of cell-surface HSPG
revealed the lymphoid cell lines to be HSPG-deficient, in contrast to HeLa and normal CHO cells.
While the reduction can be related in part to the absence of HSPG, other cellular mechanisms can also
be involved. Of interest in this respect was the finding that, in an HSPG-deficient mutant CHO cell line
(CHO-pgsA745), binding of and transduction by Ad5F35-EGFP was also reduced in the presence of FX.
This suggests that, in addition to the lack of HSPGs, other FX-mediated mechanisms are involved. Since
CHOpgsA745 cells lack CD46, and FX treatment reduced Ad5F35-EGFP binding and transduction,
this might suggest that other, unidentified molecules are responsible for these downregulatory effects
of FX on Ad5F35-EGFP binding to and transduction of CHO cells. Such mechanisms may operate at
the cell surface and/or within the cell, since previous studies have suggested that post-internalization
pathways may be affected by FX in normal CHO cells transduced by Ad5F35 viruses [15,29].
In conclusion, lymphoid cells in culture or in blood appear to be protected from Ad infection by
either a low expression of CAR (which protects cells from infection by most Ads) or by a FX-mediated
downregulation of binding and intracellular trafficking by Ads containing a fiber that binds CD46,
a complement inhibitor molecule expressed on immune cell types.
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